NCT03711890

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

Suspended NA Last updated 30 March 2025

What this trial tests

NA trial testing Optical Coherence Tomography in Pancreatic Carcinoma in 75 participants. Suspended.

Timeline

26 March 2019

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	NA
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	75
Start date	26 March 2019
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across United States

Drugs / interventions tested

• Optical Coherence Tomography
• Therapeutic Conventional Surgery
• Laboratory Evaluation

Conditions studied

• Pancreatic Carcinoma — all drugs for Pancreatic Carcinoma →
• Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type — all drugs for Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Pancreatic Carcinoma or Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer. Ultra-high resolution optical coherence tomography may help to accurately identify pancreatic cancer in resected pancreatic specimens.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
   Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
2. Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
   Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709
3. Small extracellular vesicles: from mediating cancer cell metastasis to therapeutic value in pancreatic cancer.
   Zhang W, Xing J, Liu T, Zhang J, et al · · 2022 · cited 24× · PMID 34980146 · DOI 10.1186/s12964-021-00806-y
4. Exosomes and solid cancer therapy: where are we now?
   Zemanek T, Danisovic L, Nicodemou A. · · 2025 · cited 15× · PMID 39961904 · DOI 10.1007/s12032-025-02626-3
5. Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer.
   Jurj A, Pop-Bica C, Slaby O, Ştefan CD, et al · · 2020 · cited 14× · PMID 33080788 · DOI 10.3390/ijms21207688
6. Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease-From Early Cancer Detection to Individualized Cancer Treatment.
   David P, Mittelstädt A, Kouhestani D, Anthuber A, et al · · 2023 · cited 10× · PMID 37046585 · DOI 10.3390/cancers15071924
7. The Importance of Detecting, Quantifying, and Characterizing Exosomes as a New Diagnostic/Prognostic Approach for Tumor Patients.
   Logozzi M, Orefice NS, Di Raimo R, Mizzoni D, et al · · 2023 · cited 9× · PMID 37296842 · DOI 10.3390/cancers15112878
8. Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage.
   Schiano C, Balbi C, de Nigris F, Napoli C. · · 2023 · cited 7× · PMID 37108672 · DOI 10.3390/ijms24087509